Bosutinib Treatment Guidelines: In-depth understanding of its contraindications and groups of caution

Bosutinib (Bosutinib), as an important drug for the treatment of chronic Ph+ chronic myeloid leukemia (CML), has attracted much attention due to its significant efficacy. Whether they are newly diagnosed patients, patients who are resistant or intolerant to previous treatments, or even patients in the accelerated or blast phase, bosutinib provides them with treatment hope. However, before receiving treatment, patients and their families must fully understand the contraindications and caution groups of the drug to ensure the safety of the drug.

1. Contraindications

This drug should not be used in patients with an allergic reaction to bosutinib or any of its components. Anaphylaxis may include, but is not limited to, rash, difficulty breathing, laryngeal edema and other serious symptoms, and may even be life-threatening. Before taking the drug, patients should undergo allergy testing and receive treatment under the close supervision of a doctor.

2. Use groups with caution

1. The elderly: As age increases, the liver and kidney functions of the elderly may gradually decline, and the drug metabolism rate will also slow down accordingly. Therefore, elderly patients should be particularly cautious when receiving bosutinib treatment and adjust the dosage according to the doctor’s recommendations.

2. Pregnant and lactating women: Bosutinib may have adverse effects on the fetus and infant, so pregnant and lactating women should use it with caution. Female patients should take a pregnancy test before use and use effective contraception during treatment. Nursing women should avoid breastfeeding during treatment.

3. Patients with liver damage: For patients with existing liver damage, the starting dose of bosutinib should be appropriately reduced. During treatment, doctors will regularly monitor liver enzyme levels based on the patient's liver function and adjust the medication regimen as needed.

4. Patients with renal impairment: Patients with renal impairment need to pay special attention to changes in glomerular filtration rate when using bosutinib. For patients with pre-existing renal impairment or risk factors for renal dysfunction, physicians may consider reducing the starting dose or adjusting the treatment regimen. During treatment, patients should have their kidney function monitored regularly.

5. Patients with cardiovascular disease: Bosutinib may cause adverse reactions in the cardiovascular system, such as hypertension, bradycardia, etc. Therefore, for patients with a history of cardiovascular disease, such as hypertension, heart disease, etc., bosutinib should be used with caution, and blood pressure, heart rate and other indicators should be monitored regularly. If there are any abnormalities, the doctor should be informed promptly and the treatment plan should be adjusted.

In short, before receiving bosutinib treatment, patients should inform their doctors in detail about their health status, past medical history, and other drugs they are taking. This helps doctors comprehensively assess a patient's treatment risks and develop a personalized treatment plan. At the same time, patients should strictly follow the doctor's instructions when taking medications and receive regular examinations and monitoring to ensure that the treatment effect is maximized and is safe and controllable. It should be noted that the sales price of bosutinib may vary in different regions, and patients should choose a suitable version based on their own needs and financial ability.